[Participation of endothelium-derived vasoconstrictor factors in arterial hypertension]

Vascular endothelial cells synthesize and release vasodilator (nitric oxide, prostacyclin, endothelium-derived hyperpolarizing factor) and vasoconstrictor factors (thromboxane A2, prostaglandin H2, endothelin 1), which play a key role in the local regulation of vascular tone and participate in a crucial manner in the regulation of blood pressure. Hypertension has been shown to be associated with functional changes in the endothelium. In fact, decreased endothelium-dependent relaxations and increased endothelium-dependent contractions have been reported in both conduit arteries and resistance arteries obtained from various animal models of hypertension. During hypertension, the vessel wall experiences changes in the balance of the oxidative and the antioxidative enzyme system, resulting in increases in O2- release. This contributes to endothelial dysfunction by nitric oxide oxidation and the subsequent formation of peroxynitrite (ONOO-), a potent oxidant and potential mediator of vascular tissue injury. Finally, hypertension also allows the action or the production of vasoconstrictor factors such as endothelin 1 and thromboxane A2. As a consequence of these mechanisms, basal and/or stimulated nitric oxide availability is reduced, allowing vasoconstrictor systems, such as angiotensin II, sympathetic nervous system and others to over-express their actions. The mechanisms responsible for the alterations leading to endothelial dysfunction not only affect vasomotor tone, but also platelet aggregation and coagulation mechanisms.